Faruqi and Faruqui, LLP Logo
Share this page

Whistleblower/False Claims Litigation

The False Claims Act allows whistleblowers to sue those who commit fraud against the government and to receive a portion of the recovered funds. The law covers fraud involving any government-funded contract or program, including Medicare, Medicaid, military, transportation, housing, educational, agricultural, or other program. Separate IRS, SEC and CFTC whistleblower programs cover federal tax fraud, securities and commodities fraud. Since 1986, whistleblowers have helped the government to recover more than $35 billion by bringing lawsuits under the federal and state False Claims Acts. A whistleblower can receive between 15 and 30 percent of the government's recovery.

Faruqi & Faruqi's False Claims Litigation Department represents whistleblowers nationwide in all types of fraud, including Medicare and Medicaid fraud, pharmaceutical, educational, financial, pharmacy, government contractor and defense contractors' fraud. In addition, we represent clients in matters involving bribery under the Foreign Corrupt Practices Act and in matters involving violations of securities, commodities and tax laws under the SEC, CFTC and IRS whistleblower awards programs. Our attorneys have represented whistleblowers in pharmaceutical, financial, health care, defense, and government contractor cases, with settlements totaling over $5.0 billion. Among these settlements was a $1.6 billion settlement against Abbott Laboratories related to off-label promotion and payment of kickbacks for anti-seizure drug Depakote, a $3 billion settlement against GlaxoSmithKline related to unlawful marketing tactics and kickbacks for GSK drugs, and a $491 million recovery against Pfizer involving illegal promotion of its kidney transplant drug Rapamune. Our attorneys assisted the government's investigation and prosecution of alleged False Claims Act (FCA) violations at a uranium enrichment facility in the state of Kentucky by one of the largest government defense contractors; alleged violations under a Government Services Administration (GSA) contract by a leading provider of security products; and alleged violations under a GSA contract of a leading copying and postage provider. Our attorneys have been involved in numerous investigations and pending cases against large health care providers for Medicare and Medicaid fraud, including violations of Anti-Kickback Statute and Stark law. The firm currently represents a whistleblower in an unsealed case United States of America, ex rel. Ronald J. Streck v. Allergan, Inc. et al., No. 2:08-cv-05135 (E.D. Pa.) against a number of top brand-name prescription drug manufacturers. The lawsuit stems from allegations that several pharmaceutical companies underreported Average Manufacturer Prices, enabling them to underpay rebates on pharmaceuticals sold through the states' Medicaid programs. For more information, please visit our FCA website at www.whistlebloweramerica.com.